---
title: "Bristol Myers Squibb Co. Stock Underperforms Thursday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299363077.md"
description: "Bristol Myers Squibb (BMY) shares fell 1.19% to $62.84 on Thursday, underperforming the broader market and key competitors like Johnson & Johnson and Pfizer. This marks the stock's third consecutive day of losses, leaving it 8.45% below its 52-week high. Trading volume reached 12.1 million, exceeding the 50-day average."
datetime: "2026-09-17T20:36:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299363077.md)
  - [en](https://longbridge.com/en/news/299363077.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299363077.md)
generator: "portal-rs"
---

# Bristol Myers Squibb Co. Stock Underperforms Thursday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Bristol Myers Squibb Co. (BMY) shed 1.19% to $62.84 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 1.14% to 7,637.76 and the Dow Jones Industrial Average rising 0.61% to 51,778.04.

This was the stock's third consecutive day of losses.

Bristol Myers Squibb Co. closed 8.45% below its 52-week high of $68.64, which the company achieved on August 19th.

The stock underperformed when compared to some of its competitors Thursday, as Johnson & Johnson (JNJ) rose 1.10% to $270.22, Pfizer Inc. (PFE) rose 0.66% to $27.64, and Abbott Laboratories (ABT) fell 0.13% to $102.23.

Trading volume (12.1 M) eclipsed its 50-day average volume of 10.1 M.

Data source: Dow Jones Market Data, FactSet. Data compiled September 17, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

09-17-26 1636ET

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant In Adults With Idiopathic Pulmonary Fibrosis Met Primary Endpoint](https://longbridge.com/en/news/301578258.md)
- [BUZZ-Bristol Myers rises on positive trial results for cancer and lung disease drugs](https://longbridge.com/en/news/301590676.md)
- [Bristol Myers Squibb says ZENBEXUS combo cuts multiple myeloma progression risk 51% in Phase 3 EXCALIBER-RRMM trial](https://longbridge.com/en/news/301263394.md)
- [Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%](https://longbridge.com/en/news/301304214.md)
- [BUZZ-Contineum tumbles as Bristol's partial trial win raises dose doubts](https://longbridge.com/en/news/301592637.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**